Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2019

View Archived Issues

New ultrasensitive tau seed amplification assay for detection and subtyping of 4-repeat tauopathies

Replimune begins phase I study of RP-2 alone and with Opdivo in advanced solid tumors

Ozanimod demonstrates early histologic improvement in patients with active CD

Phase IIb data for upadacitinib as an induction therapy for patients with UC

SUVN-K-1806045 demonstrates analgesia in models of nociception and diabetic neuropathic pain

Preclinical results presented of a gene therapy for the treatment of retinitis pigmentosa

New antibiotic class fights colistin-resistant bugs

Metastases, tumors, similar in broad view, different in detail

Betta Pharmaceuticals divulges new PD-1/PD-L1 interaction inhibitors

Silverback Therapeutics discloses TGFR-1 inhibitors

Merck & Co. presents new hSTING agonists

FUJIFILM synthesizes beta-lactams

Y-mAbs announces presentation of data on naxitamab for neuroblastoma and osteosarcoma

TaiMed Biologics discontinues development of TMB-607

Antimalarial agents detailed in UCB patent

Arcutis plans phase III program with ARQ-151 for plaque psoriasis

Heat Biologics initiates first-in-human study of HS-130 with HS-110 in solid tumors

Molecular Targets meeting 2019: Bispecific matchmakers can improve antibodies, CARs

Zosano initiates enrollment in phase II/III study of C-213 for cluster headache

New phase II trial investigates JNJ-67864238 for moderate to severely active Crohn's disease

Novel class I HDAC inhibitor R8 demonstrates efficacy both in vitro and in vivo

CLN-081 begins first-in-human study for NSCLC with EGFR exon 20 insertion mutations

GlaxoSmithKline begins phase III development of gepotidacin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...